financetom
Business
financetom
/
Business
/
X global affairs head Nick Pickles resigns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
X global affairs head Nick Pickles resigns
Sep 6, 2024 6:03 AM

(Reuters) - X's global affairs head Nick Pickles said on Thursday he is quitting after a decade with the social media company formerly called Twitter.

Pickles, who joined the company in 2014, said he had decided to leave X several months ago and was working with the Chief Executive Linda Yaccarino through the transition.

"After more than ten years, tomorrow will be my last day at X. It's been an incredible journey," he said.

It was not immediately clear what his next plans were, or why he made the decision to quit.

Elon Musk-owned X and Nick Pickles did not immediately respond to Reuters requests for comment outside of regular business hours.

In June, X's head of business operations, Joe Benarroch left the company, the Wall Street Journal reported, citing people familiar with the matter.

Pickles had started at X as a senior manager in their London office and was appointed the Vice President of Global Affairs for X in 2023 after serving in multiple roles, his LinkedIn profile showed.

The Financial Times reported that he was the company's spokesperson in battles with multiple governments, including in Brazil, which said last week it was suspending access to the social network in the country.

The popular social media platform missed a court-imposed deadline to name a legal representative in Brazil, triggering the suspension.

Musk has argued that Supreme Court Justice Alexandre de Moraes was trying to enforce unjustified censorship, while the judge has insisted that X needs hate speech regulations.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer
Sector Update: Consumer
Oct 6, 2025
08:56 AM EDT, 10/06/2025 (MT Newswires) -- Consumer stocks were mixed premarket Monday, with the Consumer Staples Select Sector SPDR Fund (XLP) down 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) 0.6% higher. Toyota Motor ( TM ) Chairman Akio Toyoda's proposal to buy out Toyota Industries has been delayed amid a longer-than-expected approval process under antitrust laws...
High Flood and Hurricane Scores Seen For Municipal Bond Offerings This Week
High Flood and Hurricane Scores Seen For Municipal Bond Offerings This Week
Oct 6, 2025
08:56 AM EDT, 10/06/2025 (MT Newswires) -- Multiple municipal bond offerings this week have a high exposure to climate risk, specifically high Flood and Hurricane Scores, according to ICE Climate Data. A $12 million offering from Center Moriches Union Free School District, N.Y., records a Flood Score of 4.8 out of 5.0, ICE reports. Locations with a component Physical Climate...
MedX Health Raises $528,000 in Initial Closing of $2.5 Million Private Placement
MedX Health Raises $528,000 in Initial Closing of $2.5 Million Private Placement
Oct 6, 2025
08:56 AM EDT, 10/06/2025 (MT Newswires) -- MedX Health ( MDXHF ) over the weekend said it completed the initial closing of the non-brokered private placement to accredited investors, raising cash proceeds of $527,500. The initial closing included the issuance of around 7.03 million units. Under the non-brokered private placement, the company plans to issue up to a maximum of...
Spruce Biosciences Says FDA Grants Breakthrough Therapy Designation for Tralesinidase Alfa in Sanfilippo Syndrome
Spruce Biosciences Says FDA Grants Breakthrough Therapy Designation for Tralesinidase Alfa in Sanfilippo Syndrome
Oct 6, 2025
08:57 AM EDT, 10/06/2025 (MT Newswires) -- Spruce Biosciences ( SPRB ) said Monday that its tralesinidase alfa enzyme replacement therapy, or TA-ERT, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration for the treatment of Sanfilippo Syndrome Type B. The FDA's decision was supported by long-term clinical data showing normalization of heparan sulfate non-reducing ends...
Copyright 2023-2026 - www.financetom.com All Rights Reserved